ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)

also known as antithymocyte globulin · ATG · Thymoglobulin · horse antithymocyte globulin · h-ATG · ATGAM · rATG · Equine Anti-thymocyte globulin · +19 more

Protein / enzyme biologic

Developed for: myelodysplastic syndrome · leukemia · aplastic anemia · graft versus host disease · myelodysplastic/myeloproliferative disease · myeloproliferative neoplasm · plasma cell neoplasm · type 1 diabetes mellitus
+56 more
· acute leukemia · disease related to hematopoietic stem cell transplant · Fanconi anemia · plasma cell myeloma · Hodgkins lymphoma · lymphoma · severe congenital neutropenia · Diamond-Blackfan anemia · kidney cancer · myelofibrosis · acquired aplastic anemia · atypical chronic myeloid leukemia, BCR-ABL1 negative · breast cancer · cancer · Chediak-Higashi syndrome · childhood malignant neoplasm · chronic myelomonocytic leukemia · congenital amegakaryocytic thrombocytopenia · hematopoietic and lymphoid cell neoplasm · immunodeficiency disease · juvenile myelomonocytic leukemia · multiple sclerosis · neuroblastoma · non-Hodgkin lymphoma · Shwachman-Diamond syndrome · sickle cell disease · systemic sclerosis · thalassemia · X-linked lymphoproliferative syndrome · acute graft versus host disease · acute liver failure · acute myeloid leukemia · anemia · B-cell chronic lymphocytic leukemia · benign neoplasm · central nervous system vasculitis · cerebellar degeneration · chronic inflammatory demyelinating polyradiculoneuropathy · cytomegalovirus infection · disease arising from reactivation of latent virus · GATA2 deficiency with susceptibility to MDS/AML · Griscelli syndrome · ischemic disease · Lambert-Eaton myasthenic syndrome · Langerhans cell histiocytosis · liver failure · melanoma · myasthenia gravis · neuromyelitis optica · opsoclonus-myoclonus syndrome · Rasmussen subacute encephalitis · refractory plasma cell neoplasm · stiff-person syndrome · systemic lupus erythematosus · hematologic disorder · transplant rejection
Investigated by: National Cancer Institute (NCI) · Fred Hutchinson Cancer Center · Masonic Cancer Center, University of Minnesota · National Heart, Lung, and Blood Institute (NHLBI) · Peking University People's Hospital · Nanfang Hospital, Southern Medical University
+82 more
· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · University of California, San Francisco · Asan Medical Center · Chinese PLA General Hospital · City of Hope Medical Center · Columbia University · Genzyme, a Sanofi Company · National Institute of Allergy and Infectious Diseases (NIAID) · Roswell Park Cancer Institute · Ann & Robert H Lurie Children's Hospital of Chicago · Barbara Ann Karmanos Cancer Institute · First Affiliated Hospital of Guangxi Medical University · Fujian Medical University · Fujian Medical University Union Hospital · Guangzhou General Hospital of Guangzhou Military Command · Immune Tolerance Network (ITN) · M.D. Anderson Cancer Center · Memorial Sloan Kettering Cancer Center · Sanofi · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · University of Alabama at Birmingham · Alliance for Clinical Trials in Oncology · American Diabetes Association · Amgen · Assiut University · Beijing 302 Hospital · Beth Israel Deaconess Medical Center · Blood and Marrow Transplant Group of Georgia · Camillo Ricordi and Jay Skyler · Central South University Xiangya Hospital · Chinese Academy of Medical Sciences · Daihong Liu · Diabetes Research Institute Foundation · Eledon Pharmaceuticals · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · European Society for Blood and Marrow Transplantation · Fairview University Medical Center · Guangdong Provincial People's Hospital · Guangzhou First People's Hospital · H. Lee Moffitt Cancer Center and Research Institute · Haukeland University Hospital · ITB-Med LLC · Institut Paoli-Calmettes · Jonsson Comprehensive Cancer Center · Juvenile Diabetes Research Foundation · Mayo Clinic · Milton S. Hershey Medical Center · National Center for Research Resources (NCRR) · National Institutes of Health Clinical Center (CC) · National Marrow Donor Program · Neal Young, M.D. · Northside Hospital, Inc. · Northwestern Memorial Hospital · Office of Rare Diseases (ORD) · Oxford University Hospitals NHS Trust · PETHEMA Foundation · Peking University People's Hospital, Peking University Institute of Hematology · Rare Diseases Clinical Research Network · SWOG Cancer Research Network · Southern Medical University, China · Stanford University · Targazyme, Inc. · Tatsuo Kawai, MD, PhD · The Cleveland Clinic · The First Affiliated Hospital of Zhengzhou University · The Leona M. and Harry B. Helmsley Charitable Trust · Third Affiliated Hospital, Sun Yat-Sen University · Tongji Hospital · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · University Health Network, Toronto · University of California, Los Angeles · University of California, San Diego · University of Colorado, Denver · all 88 on the full record

Trials 109 · started per year

today

199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT06972069	May 2025 → Dec 2030 expected	disease related to solid organ transplantation, kidney failure	Tatsuo Kawai, MD, PhD	Active not recruiting	No outcome recorded
Phase 18 trials
Phase 1	NCT05757310	Nov 2024 → Jun 2027 expected	aplastic anemia	City of Hope Medical Center	Recruiting	No outcome recorded
Phase 1	NCT04098393	Sep 2019 → Sep 2026 overdue	hematopoietic and lymphoid cell neoplasm	Memorial Sloan Kettering Cancer Center	Active not recruiting	No outcome recorded
Phase 1	NCT00697684	Jun 2008 → Dec 2020	B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, acute myeloid leukemia, myelodysplastic syndrome +1	Beth Israel Deaconess Medical Center	Completed	No outcome recorded
Phase 1	NCT00295971	Apr 2005 → Dec 2011	congenital amegakaryocytic thrombocytopenia, leukemia, myelodysplastic syndrome, severe congenital neutropenia	University of California, San Francisco	Completed	No outcome recorded
Phase 1	NCT00301951	Sep 2004 → Jul 2009	leukemia, myelodysplastic syndrome, plasma cell neoplasm	University of California, San Francisco	Completed	No outcome recorded
Phase 1	NCT00436761	May 2004 → ?	childhood malignant neoplasm	Milton S. Hershey Medical Center	Unknown	No outcome recorded
Phase 1	NCT00017641	Apr 2001 → ?	systemic lupus erythematosus	Northwestern Memorial Hospital	Unknown	No outcome recorded
Phase 1	NCT00014755	Dec 1997 → ?	multiple sclerosis	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 1/216 trials
Phase 1/2	NCT07796620	Oct 2026 → Sep 2027 expected	acute leukemia, aplastic anemia, myelodysplastic syndrome	Peking University People's Hospital	Not yet recruiting	No outcome recorded
Phase 1/2	NCT07634562	Sep 2026 → Aug 2031 expected	liver failure	Stanford University	Recruiting	No outcome recorded
Phase 1/2	NCT02586831	Jun 2024	hypoglycemia, type 1 diabetes mellitus	Camillo Ricordi and Jay Skyler	Withdrawn	No outcome recorded Stop: Enrollment
Phase 1/2	NCT01983761	Nov 2013 → Mar 2014	Hodgkins lymphoma, disease related to transplantation, leukemia, myelodysplastic syndrome +1	Targazyme, Inc.	Unknown	No outcome recorded
Phase 1/2	NCT01509300	Jan 2012 → Dec 2013	acute leukemia, cancer, myelodysplastic syndrome	Asan Medical Center	Unknown	No outcome recorded
Phase 1/2	NCT01033552	Jan 2010 → Aug 2021	epidermolysis bullosa	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 1/2	NCT01105273	Jul 2009 → Jul 2012	aplastic anemia	Asan Medical Center	Completed	No outcome recorded
Phase 1/2	NCT00801931	Sep 2007 → May 2009	anemia, immunodeficiency disease, leukemia, lymphoma +1	Columbia University	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT00802113	Jun 2003 → Oct 2014	Hodgkins lymphoma, non-Hodgkin lymphoma	Columbia University	Completed	No outcome recorded
Phase 1/2	NCT00054340	Oct 2002 → Sep 2006	graft versus host disease, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease +1	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00305708	Aug 2000 → Jul 2004	Diamond-Blackfan anemia, Fanconi anemia, congenital amegakaryocytic thrombocytopenia, leukemia +1	University of California, San Francisco	Completed	No outcome recorded
Phase 1/2	NCT00365287	Jun 2000 → Dec 2005	breast cancer, kidney cancer, leukemia, myelodysplastic syndrome +1	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 1/2	NCT00630253	Feb 2000 → Oct 2020	Fanconi anemia	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 1/2	NCT00005898	Feb 2000 → ?	Fanconi anemia	University of Minnesota	Completed	No outcome recorded
Phase 1/2	NCT00167219	Nov 1999 → Jul 2022	juvenile myelomonocytic leukemia	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 1/2	NCT00003552	Jan 1999 → Oct 2002	melanoma	National Heart, Lung, and Blood Institute (NHLBI)	Terminated	No outcome recorded

Phase 258 trials · 1 met primary · 1 missed
Phase 2	NCT07216391	Jul 2026 → Nov 2029 expected	type 1 diabetes mellitus	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Recruiting	No outcome recorded
Phase 2	NCT06455319	Nov 2025 → Nov 2028 expected	type 1 diabetes mellitus	University of Florida	Recruiting	No outcome recorded
Phase 2	NCT06315309	Apr 2025 → Dec 2026 expected	acute graft versus host disease, acute leukemia, myelodysplastic syndrome, myeloproliferative neoplasm	University of Alabama at Birmingham	Recruiting	No outcome recorded
Phase 2	NCT06265584	Apr 2025 → Aug 2028 expected	acute leukemia, myelodysplastic syndrome, myeloproliferative neoplasm	University of Alabama at Birmingham	Recruiting	No outcome recorded
Phase 2	NCT06238245	Feb 2024 → Dec 2025	graft versus host disease, hematopoietic and lymphoid cell neoplasm	Beijing 302 Hospital	Unknown	No outcome recorded
Phase 2	NCT04291703	Nov 2023 → Dec 2024	type 1 diabetes mellitus	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT05303727	Aug 2022 → Aug 2027 expected	neuroblastoma	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Not yet recruiting	No outcome recorded
Phase 2	NCT04862221	Feb 2022 → Aug 2026 overdue	acute liver failure, hepatic encephalopathy, immune dysregulation, autoimmunity, and autoinflammation	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Recruiting	No outcome recorded
Phase 2	NCT05132166	Dec 2021 → Apr 2026 overdue	graft versus host disease	University Health Network, Toronto	Active not recruiting	No outcome recorded
Phase 2	NCT03602898	Jun 2021 → Sep 2023	Hodgkins lymphoma, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia +3	Fred Hutchinson Cancer Center	Withdrawn	No outcome recorded Stop: Business
Phase 2	NCT04761770	Feb 2021 → Feb 2027 expected	atypical chronic myeloid leukemia, BCR-ABL1 negative, chronic myelomonocytic leukemia, myelodysplastic syndrome	Memorial Sloan Kettering Cancer Center	Active not recruiting	No outcome recorded
Phase 2	NCT06572462	Dec 2020 → Dec 2024 overdue	cytomegalovirus infection, disease arising from reactivation of latent virus, disease related to hematopoietic stem cell transplant	Chinese PLA General Hospital	Recruiting	No outcome recorded
Phase 2	NCT04778618	Dec 2020 → Jul 2022	disease related to hematopoietic stem cell transplant	Chinese PLA General Hospital	Unknown	Met primary
Phase 2	NCT04304820	May 2020 → Dec 2024 overdue	aplastic anemia	National Heart, Lung, and Blood Institute (NHLBI)	Recruiting	No outcome recorded
Phase 2	NCT06098326	Mar 2018 → Dec 2026 expected	myelodysplastic syndrome	Asan Medical Center	Active not recruiting	No outcome recorded
Phase 2	NCT03412409	Feb 2018 → Sep 2025	acute leukemia, myelodysplastic syndrome	Peking University People's Hospital	Unknown	No outcome recorded
Phase 2	NCT03412266	Feb 2018 → Mar 2023	myelodysplastic syndrome	Peking University People's Hospital	Unknown	No outcome recorded
Phase 2	NCT03395860	May 2017 → May 2020	graft versus host disease	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Unknown	No outcome recorded
Phase 2	NCT02215200	Dec 2014 → Aug 2017	type 1 diabetes mellitus	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	Mixed
Phase 2	NCT02171104	Jul 2014 → Jan 2026 overdue	Hurler syndrome, Krabbe disease, Niemann-Pick disease type B, Niemann-Pick disease, type C2 +15	Masonic Cancer Center, University of Minnesota	Active not recruiting	No outcome recorded
Phase 2	NCT01909245	Oct 2013 → Sep 2026 overdue	type 1 diabetes mellitus	City of Hope Medical Center	Active not recruiting	No outcome recorded
Phase 2	NCT01624805	Jun 2012 → Jun 2029 expected	aplastic anemia, myelodysplastic syndrome	M.D. Anderson Cancer Center	Recruiting	No outcome recorded
Phase 2	NCT01413100	Sep 2011 → Sep 2023	systemic sclerosis	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT01116232	Aug 2010 → May 2013	graft versus host disease, leukemia, lymphoproliferative syndrome, myelodysplastic syndrome +2	Barbara Ann Karmanos Cancer Institute	Terminated	No outcome recorded Stop: Business
Phase 2	NCT00944749	Aug 2009 → Dec 2015	aplastic anemia	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 2	NCT00923364	May 2009 → Jun 2014	GATA2 deficiency with susceptibility to MDS/AML, myelodysplastic syndrome	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00716066	Jun 2008 → Dec 2025 overdue	Lambert-Eaton myasthenic syndrome, Rasmussen subacute encephalitis, central nervous system vasculitis, cerebellar degeneration +5	Fred Hutchinson Cancer Center	Active not recruiting	No outcome recorded
Phase 2	NCT00635024	May → Jul 2008	plasma cell myeloma	Mayo Clinic	Terminated	No outcome recorded
Phase 2	NCT00691015	May 2008 → Apr 2014	leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloproliferative neoplasm +1	Barbara Ann Karmanos Cancer Institute	Completed	No outcome recorded
Phase 2	NCT00617929	Jan 2008 → Oct 2014	cancer	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
Phase 2	NCT00613561	Dec 2007 → Dec 2012	immunodeficiency disease	Ann & Robert H Lurie Children's Hospital of Chicago	Unknown	No outcome recorded
Phase 2	NCT00515099	Aug 2007 → Jun 2012	type 1 diabetes mellitus	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	Missed primary Stop: Enrollment
Phase 2	NCT00589563	May 2007 → Feb 2012	graft versus host disease, infectious disease, leukemia, myelodysplastic syndrome +5	City of Hope Medical Center	Completed	No outcome recorded
Phase 2	NCT00787761	Apr 2007 → Jul 2010	kidney cancer, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease +2	Northside Hospital, Inc.	Completed	No outcome recorded
Phase 2	NCT00802568	Apr 2007 → May 2011	plasma cell myeloma	Institut Paoli-Calmettes	Completed	No outcome recorded
Phase 2	NCT00466843	Apr 2007 → Feb 2010	myelodysplastic syndrome	Office of Rare Diseases (ORD)	Unknown	No outcome recorded
Phase 2	NCT00346151	Dec 2006 → Feb 2010	—	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
Phase 2	NCT00346359	Mar 2006 → Nov 2007	graft versus host disease, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease +1	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00719849	Nov 2005 → Nov 2008	leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, plasma cell neoplasm	Fred Hutchinson Cancer Center	Terminated	No outcome recorded
Phase 2	NCT00378768	Nov 2005 → Jun 2007	plasma cell myeloma	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00611351	Jun 2005 → Feb 2008	graft versus host disease, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease +2	University of Nebraska	Completed	No outcome recorded
Phase 2	NCT01231841	Mar 2005 → Dec 2010	aplastic anemia	The Cleveland Clinic	Completed	No outcome recorded
Phase 2	NCT01056614	Sep 2004 → Aug 2005	acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22), acute myeloid leukemia with t(8;21)(q22;q22) translocation, acute myeloid leukemia, del(5q31-q32) +7	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00217386	Mar 2004 → Dec 2007	leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00074269	Jul 2003 → Mar 2008	breast cancer	University of California, San Diego	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00053196	Dec 2002 → Nov 2006	leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell myeloma	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded
Phase 2	NCT00303719	Mar 2002 → May 2019	kidney cancer, leukemia, myelodysplastic syndrome, plasma cell myeloma	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
Phase 2	NCT00016419	Aug 2001 → Jul 2003	leukemia, myelodysplastic syndrome	SWOG Cancer Research Network	Completed	No outcome recorded
Phase 2	NCT00017550	Sep 2000 → Nov 2003	myelodysplastic syndrome	Genzyme, a Sanofi Company	Completed	No outcome recorded
Phase 2	NCT00016458	Jun 2000 → ?	systemic sclerosis	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00005937	Jun 2000 → Mar 2008	myelodysplastic syndrome	Neal Young, M.D.	Completed	No outcome recorded
Phase 2	NCT00001964	Mar 2000 → Dec 2003	acquired aplastic anemia	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 2	NCT00005853	Dec 1999 → Aug 2005	leukemia, myelodysplastic syndrome	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00001839	Dec 1998 → May 2000	myelodysplastic syndrome	National Institutes of Health Clinical Center (CC)	Completed	No outcome recorded
Phase 2	NCT00003913	Dec 1998 → Aug 2005	leukemia, lymphoma, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00001749	Jul 1998 → Jul 2005	Fanconi anemia	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 2	NCT00001626	Jun 1997 → Feb 2001	aplastic anemia	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 2	NCT00005852	Jun 1996 → Jul 2007	graft versus host disease, leukemia, myelodysplastic syndrome, myeloproliferative neoplasm +1	H. Lee Moffitt Cancer Center and Research Institute	Terminated	No outcome recorded Stop: Enrollment

Phase 2/36 trials
Phase 2/3	NCT03295058	Jan → Dec 2019	aplastic anemia	Assiut University	Unknown	No outcome recorded
Phase 2/3	NCT03631563	Mar 2013 → Dec 2018	graft versus host disease	Fujian Medical University	Unknown	No outcome recorded
Phase 2/3	NCT01019876	Sep 2002 → Sep 2021	Fanconi anemia, bone marrow failure syndrome, osteopetrosis, severe combined immunodeficiency	Columbia University	Completed	No outcome recorded
Phase 2/3	NCT00176852	Jun 2002 → Mar 2014	Diamond-Blackfan anemia, Shwachman-Diamond syndrome, severe congenital neutropenia, sickle cell disease +1	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2/3	NCT00176826	Sep 2000 → Aug 2012	Chediak-Higashi syndrome, Griscelli syndrome, Langerhans cell histiocytosis, X-linked lymphoproliferative syndrome	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
Phase 2/3	NCT00003816	Oct 1998 → Jul 2019	benign neoplasm, childhood malignant neoplasm, leukemia, lymphoma +3	Roswell Park Cancer Institute	Completed	No outcome recorded
Phase 36 trials
Phase 3	NCT07862127	Aug 2026 → Aug 2028 expected	disease related to hematopoietic stem cell transplant	Daihong Liu	Recruiting	No outcome recorded
Phase 3	NCT05166967	Jan 2022 → Feb 2024	disease related to hematopoietic stem cell transplant	Chinese PLA General Hospital	Completed	No outcome recorded
Phase 3	NCT03477500	Mar 2018 → Nov 2026 expected	multiple sclerosis	Haukeland University Hospital	Active not recruiting	No outcome recorded
Phase 3	NCT01239563	Jan 2011 → May 2012	ischemic disease	University of Oxford	Unknown	No outcome recorded
Phase 3	NCT01163942	Mar 2001 → Jun 2008	aplastic anemia	European Society for Blood and Marrow Transplantation	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00004474	Sep 1998 → Aug 2007	aplastic anemia	Roswell Park Cancer Institute	Completed	No outcome recorded
Phase 45 trials · 1 met primary · 1 missed
Phase 4	NCT04203108	Sep 2019 → Aug 2021	—	Nanfang Hospital, Southern Medical University	Unknown	No outcome recorded
Phase 4	NCT03608059	Jul 2018 → Aug 2023	myeloid neoplasm	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Completed	Missed primary
Phase 4	NCT01883180	Jun 2013 → Sep 2017	disease related to hematopoietic stem cell transplant, viral infectious disease	Nanfang Hospital, Southern Medical University	Completed	Met primary
Phase 4	NCT01997372	Dec 2010 → Dec 2013	acquired aplastic anemia	Chinese Academy of Medical Sciences	Unknown	No outcome recorded
Phase 4	NCT00488436	May 2002 → Jun 2007	myelodysplastic syndrome	PETHEMA Foundation	Completed	No outcome recorded
Phase not applicable9 trials · 1 met primary
—	NCT02487069	Jun 2015 → Jan 2020	acute leukemia, chronic myeloid leukemia, myelodysplastic syndrome	Nanfang Hospital, Southern Medical University	Completed	Met primary
—	NCT02162420	Jan 2015 → Aug 2024	aplastic anemia, dyskeratosis congenita	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
—	NCT02179359	Sep 2014 → Nov 2024	Diamond-Blackfan anemia, Glanzmann thrombasthenia, Shwachman-Diamond syndrome, paroxysmal nocturnal hemoglobinuria +3	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
—	NCT02643589	Jun 2013 → Jun 2016	disease related to hematopoietic stem cell transplant	Nanfang Hospital, Southern Medical University	Unknown	No outcome recorded
—	NCT00856388	Jan 2009 → Aug 2012	Burkitt lymphoma, Fanconi anemia, Hodgkins lymphoma, MALT lymphoma +33	Roswell Park Cancer Institute	Completed	No outcome recorded
—	NCT00093587	Aug 2004 → ?	graft versus host disease, leukemia	Jonsson Comprehensive Cancer Center	Unknown	No outcome recorded
—	NCT00301860	Jan 2003 → Mar 2007	leukemia, lymphoma	University of California, San Francisco	Terminated	No outcome recorded
—	NCT00427336	Dec 2000 → Aug 2009	aplastic anemia	M.D. Anderson Cancer Center	Completed	No outcome recorded
—	NCT00006054	Mar 2000 → Dec 2002	Bruton-type agammaglobulinemia, Chediak-Higashi syndrome, Wiskott-Aldrich syndrome, X-linked lymphoproliferative syndrome +6	Fairview University Medical Center	Terminated	No outcome recorded
Comparator or background therapy166 trials
Phase 1	NCT04571203 Background	May 2022 → Oct 2027 expected	—	Stanford University	Recruiting	No outcome recorded
Phase 1	NCT03320642 Background	Feb 2018 → Feb 2021	hematopoietic and lymphoid cell neoplasm	Incyte Corporation	Terminated	No outcome recorded
Phase 1	NCT02122081 Background	Jul 2015 → Sep 2022	acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22), acute myeloid leukemia with t(8;21)(q22;q22) translocation, acute promyelocytic leukemia +2	Sumithira Vasu	Completed	No outcome recorded
Phase 1	NCT02129582 Background	Nov 2014 → Mar 2019	B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, acute myeloid leukemia, chronic myeloid leukemia +3	Case Comprehensive Cancer Center	Completed	No outcome recorded
Phase 1	NCT02083250 Background	Mar 2014 → Nov 2021	acute lymphoblastic leukemia, acute myeloid leukemia, disease related to hematopoietic stem cell transplant, myelodysplastic syndrome	M.D. Anderson Cancer Center	Completed	No outcome recorded
Show all 166 trials opens the full record — a long page

Evidence & citations 31 cited values

Every value below carries the sentence it was read from. 287 sources stand behind the page.

Field	Value	Cited text
Known as	ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)	ChEMBL registry synonym — accepted as the source's own label CHEMBL2108981 ↗
Known as	Anti-human thymocyte immunoglobulin, equine	ChEMBL registry synonym — accepted as the source's own label CHEMBL2108981 ↗
Known as	Anti-thymocyte globulin equine	ChEMBL registry synonym — accepted as the source's own label CHEMBL2108981 ↗
Known as	antithymocyte globulin	“The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG),...” NCT04118556 ↗ 262 “A conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) combining total lymphoid irradiation (TLI) plus anti-thymocyte globulin (ATG) has been developed...” PMID 25779951 ↗ Mar 2015 “All patients received cyclophosphamide (CY), single fraction total body irradiation (TBI), and antithymocyte globulin (ATG) with or without fludarabine (FLU), followed by...” PMID 25824692 ↗ Mar 2015 “Participants will receive any one of the following systemic BATs based on the Investigator's decision: mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP),...” NCT04629833 ↗ “Anti-thymocyte globulin (ATG-rabbit, Thymoglobuline®) 0.5 mg/kg body weight iv on day -5, 1.0 mg ATG-rabbit/kg will be given iv on day -4, and 1.5 mg ATG-rabbit /kg will be...” NCT03477500 ↗ “Antithymocyte globulin (ATG Fresenius 10 mg/kg/day day -5 to -2, total dose 40 mg/kg, Fresenius, Bad Homburg, Germany) will be applied after transplantation from unrelated or...” NCT00188136 ↗ “Because sirolimus (SIR) monotherapy was successful in kidney transplantation under antithymocyte globulin (ATG), we undertook a pilot study comparing SIR monotherapy with...” PMID 18212631 ↗ Jan 2008 “low dose Antithymocyte Globulin plus low dose post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation” NCT03608059 ↗ “Anti-thymocyte globulin (ATG) is widely used in allogeneic hematopoietic stem cell transplantation (allo-HCT) to prevent severe graft-versus-host disease (GVHD) and graft failure.” PMID 41624481 ↗ Apr 2025 “Anti-Thymocyte Globulin, rabbit (r-ATG, Thymoglobulin®) is a polyclonal antibody against T-lymphocytes that is used for the prevention and treatment of acute allograft rejection.” NCT00331162 ↗ “We evaluated the role of granulocyte colony-stimulating factor (G-CSF) in patients with severe aplastic anemia (SAA) treated with antithymocyte globulin (ATG) and cyclosporine.” PMID 21233311 ↗ Jan 2011 Show 252 more sources
Known as	Antithymocyte immunoglobulin (horse)	ChEMBL registry synonym — accepted as the source's own label CHEMBL2108981 ↗
Known as	Antithymocyte Serum	“Antithymocyte Serum” NCT02727803 ↗
Known as	ATG	“The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG),...” NCT04118556 ↗ 68 “All patients received cyclophosphamide (CY), single fraction total body irradiation (TBI), and antithymocyte globulin (ATG) with or without fludarabine (FLU), followed by...” PMID 25824692 ↗ Mar 2015 “Participants will receive any one of the following systemic BATs based on the Investigator's decision: mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP),...” NCT04629833 ↗ “The purpose of this study is to determine the effects of the medication antithymocyte globulin (ATG) in adults with MDS and to determine which individuals with MDS are most...” NCT00466843 ↗ “Antithymocyte globulin (ATG Fresenius 10 mg/kg/day day -5 to -2, total dose 40 mg/kg, Fresenius, Bad Homburg, Germany) will be applied after transplantation from unrelated or...” NCT00188136 ↗ “The regimens for prophylaxis of GVHD based on 10mg/kg rabbit anti-human thymocyte immunoglobin (ATG, Thymoglobulin®, Genzyme Polyclonals S.A.S) effectively reduced the...” NCT04778618 ↗ “Because sirolimus (SIR) monotherapy was successful in kidney transplantation under antithymocyte globulin (ATG), we undertook a pilot study comparing SIR monotherapy with...” PMID 18212631 ↗ Jan 2008 “The regimens for prophylaxis of GVHD based on 10mg/kg rabbit anti-human thymocyte immunoglobin (ATG, Thymoglobin®, Genzyme Polyclonals S.A.S) effectively reduced the occurrence...” NCT05166967 ↗ “Patients were randomly assigned to receive anti-thymocyte globulin (ATG) 5 mg/kg plus standard GVHD prophylaxis or PTCy 50 mg/kg/d at days +3 and +4 plus standard GVHD prophylaxis.” PMID 38374026 ↗ Feb 2024 “Induction therapy, Anti Thymocyte Globulin (ATG): 1-2 mg/kg/day during 3-5 days for control and everolimus groups after transplant surgery and prior to randomization.” NCT01266148 ↗ “anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.” NCT05132166 ↗ Show 58 more sources
Known as	ATG Fresenius	“Antithymocyte globulin (ATG Fresenius 10 mg/kg/day day -5 to -2, total dose 40 mg/kg, Fresenius, Bad Homburg, Germany) will be applied after transplantation from unrelated or...” NCT00188136 ↗
Known as	ATG-rabbit	“Anti-thymocyte globulin (ATG-rabbit, Thymoglobuline®) 0.5 mg/kg body weight iv on day -5, 1.0 mg ATG-rabbit/kg will be given iv on day -4, and 1.5 mg ATG-rabbit /kg will be...” NCT03477500 ↗ 1 “Anti-Thymocyte Globulin, ATG (Rabbit)” NCT07634562 ↗
Known as	ATGAM	“After leukapheresis, patients will receive an antibody from horses called Atgam (ATG) to help destroy the immune system” NCT00040482 ↗ 4 “Horse ATG (ATGAM) (hATG) is not considered an investigational medicinal product (IMP)” NCT03025698 ↗ “ATG rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg” NCT01087398 ↗ “h-ATG (ATGAM )” NCT00944749 ↗ NCT06972069 ↗
Known as	Equine Anti-thymocyte globulin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02158052 ↗ 3 NCT00923364 ↗ NCT04862221 ↗ NCT01861106 ↗
Known as	Equine thymocyte immune globulin	ChEMBL registry synonym — accepted as the source's own label CHEMBL2108981 ↗
Known as	h-ATG	“Aplastic anemia can be treated effectively with allogeneic bone marrow transplantation and immunosuppressive therapy with horse anti-thymocyte globulin (h-ATG) and cyclosporine...” NCT03413306 ↗ 6 “Standard of Care immunosuppressive therapy (IST) includes HORSE ANTI-THYMOCYTE GLOBULIN (H-ATG) and Cyclosporine (CSA)” NCT07001254 ↗ “combination of hATG (horse anti-thymocyte globulin)” NCT01624805 ↗ “hATG/CsA/sirolimus to standard h-ATG/CsA” PMID 19181786 ↗ Jan 2009 NCT03025698 ↗ NCT00944749 ↗ NCT02099747 ↗
Known as	horse antithymocyte globulin	“Aplastic anemia can be treated effectively with allogeneic bone marrow transplantation and immunosuppressive therapy with horse anti-thymocyte globulin (h-ATG) and cyclosporine...” NCT03413306 ↗ 8 “Standard of Care immunosuppressive therapy (IST) includes HORSE ANTI-THYMOCYTE GLOBULIN (H-ATG) and Cyclosporine (CSA)” NCT07001254 ↗ “Horses can also be used for this procedure to make horse-antithymocyte globulin (h-ATG).” NCT00944749 ↗ “Mérieux; horse antithymocyte globulin (ATG) + Cyclosporine A (CSA)” NCT00004208 ↗ “Horse Antithymocyte Globulin, Cyclosporine, Promacta, Eltrombopag” NCT01623167 ↗ “horse antithymocyte globulin (h-ATG)” PMID 19181786 ↗ Jan 2009 NCT04304820 ↗ NCT01019876 ↗ NCT00801931 ↗
Known as	horse ATG	“Horse ATG (ATGAM) (hATG) is not considered an investigational medicinal product (IMP)” NCT03025698 ↗ 1 “standard horse ATG (h-ATG) plus cyclosporine (CsA)” PMID 24415649 ↗ Mar 2014
Known as	ImtixSangstat	“The optimal dose of rabbit antithymocyte globulin (ATG, ImtixSangstat) minimizing infections without increasing graft-versus-host disease (GVHD) is unknown” PMID 31401973 ↗ Aug 2019
Known as	lymphocyte immune globulin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04224558 ↗
Known as	rabbit anti-human thymocyte immunoglobin	“The regimens for prophylaxis of GVHD based on 10mg/kg rabbit anti-human thymocyte immunoglobin (ATG, Thymoglobulin®, Genzyme Polyclonals S.A.S) effectively reduced the...” NCT04778618 ↗
Known as	rabbit anti-thymocyte globulin	“Therefore, rabbit-anti-thymocyte globulin has hematologic remitting activity in myelodysplastic syndrome and a T-cell activation profile has potential utility classifying those...” PMID 24488560 ↗ Jan 2014 2 “rabbit anti-thymocyte globulin (ATG) IV over at least 8-12 hours on days 1-4” NCT00017550 ↗ “another drug called (rabbit Anti-thymocyte Globulin [ATG])” NCT06315309 ↗
Known as	rabbit ATG	“conditioning regimen of alemtuzumab/Campath, anti-thymocyte globulin/rabbit ATG, Fludarabine and Melphalan and total body irradiation” NCT07284641 ↗
Known as	Rabbit thymoglobulin	“Rabbit thymoglobulin will be given intravenously at a dose of 2.5 mg/kg on days -5,-4, -3, and -2.” NCT00392782 ↗
Known as	rATG	“Protocol for Prospective Phase II Study of Rabbit Antithymocyte Globulin (r-ATG/Thymoglobulin) and Cyclosporine (CsA) as a First Line Immunosuppressive (IS) Therapy for Severe...” NCT01231841 ↗ 4 “Anti-Thymocyte Globulin, rabbit (r-ATG, Thymoglobulin®) is a polyclonal antibody against T-lymphocytes that is used for the prevention and treatment of acute allograft rejection.” NCT00331162 ↗ “Individual dose of Thymoglobulin (r-ATG) : Individual dose of ATG was Intravenous infused every day from day -5 to day -2” NCT04778618 ↗ “Anti-thymocyte Globulin (rATG), as Induction Therapy” NCT04311632 ↗ “low dose antithymocyte globulin rATG(2.5mg/kg/d)” NCT03395860 ↗
Known as	Thymoglobin	“The regimens for prophylaxis of GVHD based on 10mg/kg rabbit anti-human thymocyte immunoglobin (ATG, Thymoglobin®, Genzyme Polyclonals S.A.S) effectively reduced the occurrence...” NCT05166967 ↗
Known as	Thymoglobulin	“ATG (Thymoglobulin) IV, total dose 6-10 mg/kg (PK-guided, targeting AUC 100-148.5 IU·day/mL) for experimental arm; fixed 10 mg/kg for control arm, both given over Days -5 to -3...” NCT07862127 ↗ 10 “The regimens for prophylaxis of GVHD based on 10mg/kg rabbit anti-human thymocyte immunoglobin (ATG, Thymoglobulin®, Genzyme Polyclonals S.A.S) effectively reduced the...” NCT04778618 ↗ “Antithymocyte globulin (Thymoglobulin) 1.5 mg/kg/day (for HLA-matched sibling donor HCT) or 3.0 mg/kg/day (for other alternative donor HCT) i.v. daily on days -3 to -1 (for 3 days)” NCT06098326 ↗ “Anti-Thymocyte Globulin, rabbit (r-ATG, Thymoglobulin®) is a polyclonal antibody against T-lymphocytes that is used for the prevention and treatment of acute allograft rejection.” NCT00331162 ↗ “Antithymocyte globulin, or thymoglobulin, will be given IV daily for 4 days (days 7, 5, 3, and 1 before transplant).” NCT00133367 ↗ “ATG (Thymoglobulin®, Genzyme), at a dose of 1.5 mg/kg/d, will be given intravenously on days -11 through -7.” NCT00603954 ↗ “Rabbit thymoglobulin will be given intravenously at a dose of 2.5 mg/kg on days -5,-4, -3, and -2.” NCT00392782 ↗ “rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France).” NCT03412266 ↗ “rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France)” NCT03412409 ↗ “monitoring ATG (Thymoglobulin, Sanofi, Lyon, France) concentrations” PMID 41624481 ↗ Apr 2025 “Thymoglobulin® (Anti-thymocyte Globulin) - at first transplant” NCT00789308 ↗
Known as	Thymoglobulin [Anti-thymocyte Globulin	“Thymoglobulin® [Anti-thymocyte Globulin” NCT00795132 ↗
Known as	Thymoglobuline	“The purpose of this study is to determine if anti-thymocyte globulin (Thymoglobuline) administration in the kidney transplant recipient is able to reduce the amount of damage...” NCT01239563 ↗ 2 “Anti-thymocyte globulin (ATG-rabbit, Thymoglobuline®) 0.5 mg/kg body weight iv on day -5, 1.0 mg ATG-rabbit/kg will be given iv on day -4, and 1.5 mg ATG-rabbit /kg will be...” NCT03477500 ↗ “2.5 mg/Kg/day ATG (Thymoglobuline®) for 2 consecutive days (day -2 and -1)” NCT02876679 ↗
Known as	Timoglobulin SangStat	“Antithymocyte globulin (Timoglobulin SangStat)” NCT00488436 ↗
Known as	◦Drug: ATG	“◦Drug: ATG” NCT01983761 ↗
Action	Inhibit	“Treatments to abrogate T cell activity such as anti-thymocyte globulin alone and cyclosporine alone have demonstrated varying degrees of success in alleviating the cytopenia of MDS.” NCT00005937 ↗
Modality	Protein / enzyme biologic	“horse antithymocyte globulin (ATG)” NCT00004208 ↗
Route	Intravenous	“ATG will then be started, infused through a vein continuously for 4 days” NCT00001964 ↗